Bayer, a company struggling for years to settle claims with those who say its weedkiller, Roundup, caused their non-Hodgkin’s lymphoma, reached a $2 billion settlement recently to resolve future claims, according to Reuters.
Bayer, which inherited Roundup from Monsanto in a 2018 purchase of the company, maintains that Roundup is safe for human use.
But a biological evaluation released in November by the Environmental Protection Agency states that glyphosate, an ingredient in Roundup, is likely to adversely affect a significant percent of endangered species and critical habitats.
The EPA recently extended the public comment period on the draft document. “On Jan. 12, EPA extended the public comment period on the draft BE for glyphosate to give stakeholders more time to review and comment,” an agency spokesperson said. “EPA is accepting public comments via docket EPA-HQ-OPP-2020-0585 at www.regulations.gov . The comment period will close on March 12.”
Last year LegalExaminer.com wrote about Bayer previously settling a suit by hundreds of people claiming the use of Roundup, the world’s most popular weed killer, gave them cancer. The company agreed in early summer 2020 to pay up to $10.9 billion to settle litigation over the cancer claims. At that time, there were 52,000 claimants.